anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Current recommendations for refractory status epilepticus (SE) unresponsive to benzodiazepines suggest a loading dose of levetiracetam (LEV) of 60 mg/kg to a maximum of 4500 mg. LEV therapeutic drug monitoring can help guide therapy and is garnering increasing attention. The objective of this study is to simulate the probability of target attainment (PTA) of fixed dose and weight-based loading doses of LEV with respect to established therapeutic target concentrations. Meta-regression of the current literature was performed to evaluate the relationship between intravenous LEV loading dose and seizure cessation in refractory SE patients. A previously published pharmacokinetic model was used to simulate the PTA capacity of competing single intravenous dosing schemes (fixed vs weight-based dosing) to achieve maximum (Cpeak) and 12-h (C12h) plasma concentrations that exceed 12 mg/L. The meta-regression indicated that dosage was not a statistically significant modulator of seizure control at dosages between 20 and 60 mg/kg. Stochastic simulations showed all dosing schemes achieved plasma Cpeak >12 mg/L, but C12h levels were <12 mg/L in subjects over 60 kg with a fixed dose ≤2000 mg or in subjects <60 kg with a weight-based dose <30 mg/kg. Dosages of 40 and 60 mg/kg provided ≥90% PTAs across all weights. Using a weight-based loading dose of 40 mg/kg, up to a suggested maximum of 4500 mg, improves the likelihood of achieving a sustained therapeutic drug concentration after the initial LEV dose, whereas fixed <3000 mg may not achieve the desired concentration before maintenance dosing.
Bexsero vaccine will be administered as an intramuscular injection in 1 mL single-dose prefilled syringe in two doses with a two-month apart (at enrollment/Visit 1 and Visit 3). N=1100.
Patients receive tremelimumab IV over 1 hour on day 1. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
PROBLEM TO BE SOLVED: To obtain a peeling-off type sheet-like pack having a metal oxide on the adhesive surface of the outermost surface layer and excellent in actions for removing KAKUSEN (sebum) and aged keratin. SOLUTION: This pack has a metal oxide on the adhesive surface of the outermost surface layer directly brought into contact with skin. The metal oxide is titanium dioxide, silica, etc., which has an average primary particle diameter of 5-100nm. Polyvinyl alcohol, etc., is used of the adhesive agent layer and the outermost surface layer. The pack is prepared by suitably compounding known components for cosmetic, dissolving the components, coating the mixture on a substrate, drying the coated mixture to form a sheet, dissolving the metal oxide in an adhesive agent, coating the mixture on the formed sheet, and subsequently drying the mixture.  The pack is used by coating water or a lotion on a target site for the removal of KAKUSEN (sebum) and aged keratin therefrom, tightly adhering the pack to the coated site, sufficiently drying the adhered pack, and subsequently peeling off the pack. Since a conventional agent such as polyvinyl alcohol can be used without requiring a special polymeric compound, the pack is advantageous on cost.
Acceptance-based Insight-inducing and Medication Adherence Therapy (AIM_AT) consists of 10 weekly/biweekly, 2-hour sessions (4-months), based on the modified Kemp's model/manual of Adherence therapy and mindfulness-based psychoeducation program developed by the research team. The integrative AIM_AT program based on the principles of motivational-interviewing technique (MI) and mindfulness- and acceptance-based therapy, which have been tested in our previous controlled trials and increasingly been shown to reduce both positive and negative psychotic symptoms and ambivalent attitude towards medication adherence and inducing treatment/illness insight.
NEW MATERIAL:The compound of formula I (R is 8-24C aliphatic hydrocarbon group). EXAMPLE:1-O-Methyl-6-O-n-octylgalactofuranoside. USE:A cosmetic base. PREPARATION:1,2:3,4-Di-O-isopropylidene galactopyranose obtained by the reaction of galactose with acetone is made to react with the compound of formula RX (X is halogen) in an alkaline aqueous solution in the presence of a phase- transfer catalyst (e.g. quaternary onium salt) to effect the etherification of the 6-OH group. The resultant 6-O-alkyl-1,2:3,4-di-O-isopropylidene galactopyranose of formula II is subjected to the solvolysis in methonol in the presence of an acid catalyst such as a protonic acid to effect the removal of the protecting group and obtain the objective compound of formula I .
Do not administer unless solution is clear and seal is intact. Discard unused portion.

Phosphorus replacement therapy with potassium phosphate should be guided primarily by the serum inorganic phosphorus level and the limits imposed by the accompanying potassium (K+) ion.

High plasma concentrations of potassium may cause death through cardiac depression, arrhythmias or arrest.

Use with caution in the presence of cardiac disease, particularly in digitalized patients or in the presence of renal disease.

Pregnancy: Animal reproduction studies have not been conducted with potassium phosphate. It is also not known whether potassium phosphate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Potassium phosphate should be given to a pregnant woman only if clearly needed.
Patients receive idarubicin IV and cytarabine IV as in arm I. Patients also receive clofarabine IV by push injection over 10 minutes on days 2, 4, 6, 8, and 10.
BACKGROUND: Stress urinary incontinence (SUI), though a prevalent condition among women, is undertreated in primary care. EHealth with pelvic floor muscle training is an evidence-based alternative to care-as-usual. It is unknown, however, how eHealth usage is related to treatment outcome, and this knowledge is required for general practitioners to implement eHealth in their practice. This study examines the relation between usage of eHealth for SUI and treatment outcomes by examining log data. Baseline factors were also explored for associations with treatment success.
METHOD: In this pre-post study, women with SUI participated in "Baasoverjeblaas.nl", a web-based intervention translated from the Swedish internet intervention "Tät®-treatment of stress urinary incontinence". Usage was based on log data and divided into three user groups (low, intermediate and high). Online questionnaires were sent before, after treatment and at six-months follow-up. The relation between usage and the primary outcome - treatment success (PGI-) - was studied with a binomial logistic regression analysis. Changes in the secondary outcomes - symptom severity (ICIQ-UI SF) and quality of life (ICIQ-LUTSqol) - were studied per user group with linear mixed model analysis.
RESULTS: Included were 515 users with a mean age of 50.5 years (12.0 SD). The majority were low users (n = 295, 57.3%). Treatment success (PGI-I) was reached by one in four women and was more likely in high and intermediate users than in low users (OR 13.2, 95% CI 6.1-28.5, p < 0.001 and OR 2.92, 95% CI 1.35-6.34, p = 0.007, respectively). Symptom severity decreased and quality of life improved significantly over time, especially among high users. The women's expected ability to train their pelvic floor muscles and the frequency of pelvic floor muscle exercises at baseline were associated with treatment success.
CONCLUSION: This study shows that usage of eHealth for SUI is related to all treatment outcomes. High users are more likely to have treatment success. Treatment success is more likely in women with higher expectations and pelvic floor muscle training at baseline. These findings indicate that general practitioners can select patients that would be more likely to benefit from eHealth treatment, and they can enhance treatment effect by stimulating eHealth usage.
TRIAL REGISTRATION: Landelijk Trial Register NL6570;  https://onderzoekmetmensen.nl/nl/trial/25463 .
H2S-donors are cardioprotective in ischemia/reperfusion (I/R) injury. Some H2S-donors exert their beneficial effects in a nitric oxide (NO)-dependent manner, while others act using NO-independent pathways. The aims of the present study were to (i) evaluate whether H2S-donors with distinct pharmacodynamic properties act synergistically in I/R injury and (ii) determine if H2S-donors remain cardioprotective in obese mice. C57BL/6 mice were subjected to 30 min of ischemia followed by 120 min of reperfusion. Donors were administered intravenously at the end of ischemia (Na2S: 1 μmol/kg, GYY4137: 25 μmol/kg, AP39: 0,25 μmol/kg), while the 3-mercaptopyruvate sulfurtransferase (10 mg/kg) inhibitor was given intraperitonially 1 h prior to ischemia. Infarct size was estimated by 2,3,5-triphenyltetrazolium staining, while the area at risk was calculated using Evans blue. All three donors reduced infarct size when administered as a sole treatment. Co-administration of Na2S/GYY4137, as well as Na2S/AP39 reduced further the I/R injury, beyond what was observed with each individual donor. Since inhibition of the H2S-producing enzyme 3-mercaptopyruvate sulfurtransferase is known to reduce infarct size, we co-administered C3 with Na2S to determine possible additive effects between the two agents. In this case, combination of C3 with Na2S did not yield superior results compared to the individual treatments. Similarly, to what was observed in healthy mice, administration of a H2S-donor (Na2S or AP39) reduced I/R injury in mice rendered obese by consumption of a high fat diet. We conclude that combining a NO-dependent with a NO-independent H2S-donor leads to enhanced cardioprotection and that H2S-donors remain effective in obese animals.
Methods and apparatus for computer-aided prostate condition diagnosis are disclosed. An example computer-aided prostate condition diagnosis apparatus includes a memory to store instructions and a processor. The example processor is to execute the instructions to implement at least a prostate assessor, a lesion assessor, and an outcome generator. The example prostate assessor is to evaluate a volume and density of a prostate gland in an image of a patient to determine a prostate-specific antigen level for the prostate gland. The example lesion assessor is to analyze a lesion on the prostate gland in the image. The example outcome generator is to generate an assessment of prostate gland health based on the prostate-specific antigen level and the analysis of the lesion.
PURPOSE: To obtain a formulated composition comprising a cell-protecting copolymer and a directly acting antitumor agent and capable of reducing a side effect without affecting its tumor cytotoxic effect. CONSTITUTION: This formulated composition comprises a cell-protecting half- amide and half-imide copolymer composed of a monomer unit having half amide and half carboxyl groups of formula I (X is hydride or an alkyl; Y is hydride, ammonium or a pharmaceutically acceptable metal cation) and a monomer unit having an imide group of formula II (Z is Y or an alkyl), e.g. the one obtained by copolymerizing a 2-4C olefin monomer (e.g. ethylene) and a 4-6C α,β-unsaturated polycarboxylic anhydride (e.g.  maleic anhydride) to form a copolymer having 300-1800 average molecular weight, and introducing the half amide group, the half carboxyl group and the imide group to the copolymer to have 5-40wt.% imide group in the groups of formulas I and II, an introduced N-alkylated group and an introduced cationic group and further to have the introduced N-alkylated group in which the alkyl is a 1-4C alkyl, and a directly acting antitumor agent (e.g. antimetabolism type, alkylation type and antibiotic type antitumors).
Grade 3 or 4 neutropenia occurred in 41% to 44% of patients with colorectal cancer who received oxaliplatin injection with fluorouracil/leucovorin. Sepsis, neutropenic sepsis and septic shock, including fatal outcomes, occurred in patients who received oxaliplatin injection [see Adverse Reactions (6.1, 6.2)].

Grade 3 or 4 thrombocytopenia occurred in 2% to 5% of patients with colorectal cancer who received oxaliplatin injection with fluorouracil/leucovorin. 

Monitor complete blood cell count at baseline, before each subsequent cycle and as clinically indicated. Delay oxaliplatin injection until neutrophils are greater than or equal to 1.5 x 109/L and platelets are greater than or equal to 75 × 109/L. Withhold oxaliplatin injection for sepsis or septic shock. Dose reduce oxaliplatin injection after recovery from grade 4 neutropenia, febrile neutropenia or grade 3-4 thrombocytopenia as recommended [see Dosage and Administration (2.2)].
Participants ingested 2,200 mg/day of a placebo or active dietary supplement. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks. The supplements were prepared in caplet form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.
The two key elements of the PUER Research protocol include (1) molecular and laboratory profiling and (2) non-invasive imaging and wearables/ "quantified self" measurements. All elements are optional. Molecular assessments will be conducted using peripheral blood samples, and potentially urine, stool or saliva samples. Non-invasive imaging assessment will consist of magnetic resonance imaging (MRI) and computerized tomography (CT) scans, ultrasound, and x-ray. All imaging modalities are optional. Other functional assessments, including respiratory, cardiac and other functions, as well as self-quantifiable assessments via wearables, may also be conducted and are optional.

The study will result in longitudinal data collection to inform if any modalities employed here can inform of baseline deviations for individuals. Researchers at study sites will not be blinded to the data being collected during this study.
Patients receive cetuximab IV over 120 minutes on week 1 and over 60 minutes once weekly on weeks 2-7. Patients undergo IMRT as in Arm I and receive concurrent docetaxel once weekly for 6 weeks. Patients undergo collection of blood samples during screening and throughout the study and may undergo CT scans and/or MRI and biopsy as clinically indicated on study.
PROBLEM TO BE SOLVED: To provide a protective vaccine against meningococcal serogroups W135 and H.influenzae type b disease.SOLUTION: Conjugated capsular saccharides from meningococcal serogroups C, serogroups W135 and serogroups Y are safe and immunogenic in humans when combined in a single dose. These conjugated antigens can be stably combined in a single aqueous dose without the need for lyophilization. Broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. These polypeptide antigens can be combined with the saccharide antigens without loss of protective efficacy for any of the five serogroups. The efficacy of a serogroup W135 conjugate is enhanced by addition of protein antigens derived from a serogroup B strain. Addition of an Hib conjugate to meningococcal conjugates enhances the overall activity against meningococcal serogroup W135.
The present invention relates to a newly identified human dynamin belonging to the superfamily of mammalian GTPases. The invention also relates to polynucleotides encoding the dynamin. The invention further relates to methods using the dynamin polypeptides and polynucleotides as a target for diagnosis and treatment in dynamin-mediated or -related disorders. The invention further relates to drug-screening methods using the dynamin polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the dynamin polypeptides and polynucleotides. The invention further relates to procedures for producing the dynamin polypeptides and polynucleotides.
A patient monitoring apparatus includes at least one transducer for a patient, a transmission device for the patient and a reception device which is remote therefrom and to which an evaluation unit is connected. The transmission and reception devices each have at least one memory. The memory in the transmission unit stores an explicit or unique unalterable identification code. The reception unit has a keypad which can be used to input an identification code into its memory. A radio link between the transmission and reception units is set up only if the two stored identification codes are identical. If the radio link is interrupted for a prescribed period, the identification code in the reception unit is automatically erased, and a connection can be set up again only after the appropriate identification code has been input on the reception unit again. The radio link operates on the basis of the Bluetooth protocol.
PURPOSE:To produce easily a finely divided chitin suspension which is stable only by mechanical operation without using any chemical agents, by treating a coarsely powdered chitin suspension with a high-pressure homogenizing apparatus. CONSTITUTION:A high-pressure homogenizing apparatus is used which is operated in such a manner that a suspension which is caused to flow into a valve device 1 in the direction of an arrow is passed through a small-diameter orifice 3 between a valve seat 2 and a valve 4 to apply pressure to the suspension and to rapidly accelerate it and is made to collide with a collision ring 5 to rapidly reduce the speed. Chitin obtd. from crab or shrimp, refined and crushed to small pieces (the longest being 1-2mm.) is dispersed in water (concn. being 10wt% or below). The suspension is introduced into the homogenizing apparatus and passed therethrough while applying a pressure of at least 200kg/cm<2>, pref. 350- 560kg/cm<2> to the suspension. By repeating this stage, a chitin suspension is produced in which the content of the stabilized suspension is at least 50% after 0.5wt% suspension having a water retention value of at least 200% is left to stand for one hr.
While weight loss (2-5% of total bodyweight) with clinical interventions has been shown to improve glycemic control in patients with Type II Diabetes clinic-based interventions are costly and have poor accessibility for the majority of patients. Commercial weight loss programs like WW (formerly Weight Watchers) are more affordable and accessible than clinic-based modalities, and have been shown to produce effective weight loss in adults with additional improvements in glycemic control. A randomized trial of a modified WW program for patients with Type II Diabetes showed significant reductions in weight and improved glycemic control (HbA1c) compared to standard of care diabetes nutrition counseling and education. Here, we extend prior work by leveraging the efficacy of the WW program for Type II Diabetes, virtually, to increase its reach and its impact on glycemic control. This study aims to test a novel, web-based weight loss intervention from one of the largest and most evidence-based proprietary weight loss programs in the world.

Intervention will consist of the WW program modified for people with Type 2 diabetes including weekly Virtual Workshops and use of the WW App. Primary outcomes are any change in HbA1c% over the 6-month intervention. Secondary endpoints are any change in HbA1c% at 3 months, as well as changes at 3 and 6 months in weight, Diabetes Distress Scale, Impact of Weight on Quality of Life, Pittsburgh Sleep Quality Index, hypoglycemic events, WHO-5 Well-being Index, and diabetes medication changes.
FIELD: medicine. SUBSTANCE: bacterial mass of culture BCG-M grown in solid potato medium and then in liquid synthetic media is removed, filtered, washed out with drying medium, ground in shuttle-apparatus to obtain homogeneous mass, diluted with stabilizing agent to prepare suspension containing 50 mg of BCG/1 ml followed by centrifugation at 2 000 rev/min for 15-20 min. Then supernatant suspension is diluted again to the final concentration 0.5 mg BCG/1 ml. Vaccine is ampouled and lyophilized. EFFECT: enhanced viability in single vaccinating dose. 1 cl, 3 tbl, 1 ex
Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 4H2 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex. Compositions and methods of increasing activation of immune receptors such as cGAS and TLR7 in cells of a subject are also provided. The methods typically include administering an effective amount of a 4H2 antibody to the subject. The subject can be healthy or can have a disease or disorder such cancer or an infection.
OBJECTIVE: To assess the causal role of the relationship between loading and the onset of nonspecific low back pain (NSLBP) and persistence of NSLBP (chronic low back pain [CLBP]). DESIGN: Scoping review. LITERATURE SEARCH: We searched the literature from 2010 until May 2021 using a combination of terms related to (spinal) load and the Bradford-Hill (BH) criteria. STUDY SELECTION CRITERIA: Operational definitions were developed for every criterion of the BH framework for causality. Study selection was based on the causal role of load in the onset of NSLBP and persistence of chronic low back pain. DATA SYNTHESIS: The BH criteria were operationalized, and causation was considered established when evidence supported the BH criteria strength, temporality, biological gradient, experiment, and biological plausibility. RESULTS: Twenty-two studies were included. There was no consistent support for an association between load and the incidence of NSLBP, or that more load increased the risk of NSLBP/CLBP. Half of the studies did not support specific load exposures to increase incidence of or increase pain in NSLBP/CLBP. Half of studies did not support load preceding NSLBP. No study supported plausible biological explanations to influence the relationship between load and NSLBP/CLBP, or that similar causes have similar effects on NSLBP. Nine of 10 experimental studies did not support that load results in NSLBP or that relieving load reduces NSLBP/CLBP. CONCLUSION: There was insufficient evidence to support a causal relationship between loading and the onset and persistence of NSLBP/CLBP based on the BH criteria. These results question the role of load management as the only/primary strategy to prevent onset and persistence of NSLBP/CLBP. J Orthop Sports Phys Ther 2024;54(3):1-15. Epub 25 January 2024. doi:10.2519/jospt.2024.11314.